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 Abstract 
 
Liver disease can lead to serious impairment in cognitive functioning, through the 
development of a condition known as hepatic encephalopathy (HE).  While gross 
impairment is clinically obvious, milder variants of the condition may escape 
detection at bedside examination and yet may have a significant impact on day-to-day 
activities.  In this brief review article, the neuropsychology of liver disease is 
examined, focusing on nature, aetiology and significance.  The possible contributory 
role of endogenous benzodiazepines in HE is described, as is the evidence regarding 
the effect of benzodiazepine antagonism on cognitive functioning in HE.  The 
functional localisation of HE is briefly reviewed, as is the use of neuropsychological 
measures to evaluate treatment efficacy, e.g. following shunt procedures or liver 
transplantation.  Finally, living donor liver transplantation is described, and the case is 
made for rigorous longitudinal neuropsychological evaluation of potential donors and 
recipients. 
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Introduction 
 
Neuropsychology  is the study of brain-behaviour relationships [1].  Historically, 
neuropsychology utilised the classical lesion-based approach, i.e. relating focal brain 
damage to observed changes in behaviour and cognitive functioning.  However, many 
clinical conditions lead to impairments in cognitive functioning that cannot be 
attributed to a focal brain lesion, and liver disease is one of these conditions.   
The liver plays a key role in removing toxins from the blood, including substances 
that are neurotoxic.  When the liver becomes scarred and cirrhotic, some of the blood 
entering the liver via the portal vein cannot penetrate the diseased liver. As a result the 
blood that has not been processed by the liver is diverted into the general circulation.  
This is known as portal-systemic shunting.  As the blood that has bypassed the liver 
has not had toxins removed, the level of these toxins in the systemic circulation 
increases and the condition of Hepatic Encephalopathy (HE) can arise [2]. HE 
develops when brain function is impaired by the presence of toxins in the bloodstream 
(absorbed from the colon) which are normally removed or detoxified by the liver. 
Symptoms include drowsiness, confusion, cognitive impairment and coma. HE occurs 
only with significant liver dysfunction and has the potential for full reversibility [3-5].  
HE has traditionally been graded using the Parsons-Smith criteria, a 5 point rating 
scale ranging from Grade 0 (no abnormality detected) to Grade 4  (indicating coma) 
where mental state is not testable [6].  The overt form of HE is clinically obvious but 
recently there  has been increasing interest in the milder end of the HE continuum.  
This has been called sub-clinical, latent or mild HE.  It has been estimated that 1.5-2 
million people in North America alone may have cognitive impairment associated 
with liver disease [7] and the prevalence of subclinical HE in cirrhosis has been 
reported to range from 30-84% [8]. This wide variation in estimated prevalence is 
because there is no agreement as to what constitutes subclinical HE. The number and 
type of cognitive abnormalities that need to be present before a diagnosis of 
subclinical HE can be made differs throughout the literature. It is consequently 
impossible to produce accurate figures regarding prevalence. [9].  A consensus 
statement recently proposed a minimal cognitive test battery for the assessment of HE 
[8] , However, a disadvantage to this test battery is the inclusion of  the number 
connection test [10] which has been shown in several studies to be insensitive to mild 
HE [11, 12].  Nevertheless, there  is consistent evidence of psychomotor slowing and 
memory impairment in subclinical HE.  Oritz and colleagues have recently reported 
data suggesting that the learning and memory impairment is secondary to an 
attentional deficit caused by HE [13]. Subclinical HE may be present in the majority 
of the “healthy” ambulant, non-clinically encephalopathic cirrhotic population, for 
example,  Gitlen et al. [7] and Moore et al. [11] both reported that over 70% of 
cirrhotic patients demonstrated impairment in two or more of the cognitive tests 
employed, compared with 10% or less of those in their control groups. 
 
Significance of latent hepatic encephalopathy? 
If subtle impairment of psychomotor speed and memory is found in the majority of 
patients with liver cirrhosis, does it matter? The relationship between speed-
dependent visuo-spatial abilities and everyday activities such as driving is obvious.  
Schomerus et al. [14] estimated that 60% of their patients with subclinical HE were 
unfit to drive and a further 25% were of dubious driving ability.  Dunk and Moore 
[15] argued that such patients who drive or operate heavy machinery may put 
themselves and others at risk.  In a more recent study, it was reported that 44% of 
patients with subclinical hepatic encephalopathy were unfit to drive and that routine 
testing of cirrhotic patients for ability to drive could have a major impact on motor 
vehicle accident rates [16].  Many of the studies in this area have been limited by the 
use of driving simulations.  Wein et al. recently utilized a standardized on-road 
driving test and reported significantly impaired driving performance in many patients 
with subclinical hepatic encephalopathy. During the assessments the instructor had to 
intervene in the driving of over one-third of the patients with subclinical HE in order 
to avoid an accident, significantly more than in cirrhotic patients without HE or 
matched controls.  The authors concluded that patients with liver cirrhosis should be 
tested for mild hepatic encephalopathy and informed in the case of abnormal test 
results [17]. 
The identification of mild hepatic encephalopathy is also important for prognosis, as 
approximately 50% of patients with subclinical HE develop full clinical 
encephalopathy within 4-24 months [18] [19]. As Davies et al point out, failure to 
detect mild hepatic encephalopathy can lead to the patient being at increased risk of 
becoming clinically encephalopathic, with an associated reduction in life quality [20]. 
 
Aetiology of Hepatic Encephalopathy (HE) 
As stated above, one of the major functions of the liver is to remove toxins from the 
blood. HE is thought to develop as a consequence of biochemical disturbance of brain 
function. Evidence to support this explanation of HE is twofold: (a) it is a reversible 
phenomenon, and (b) it does not cause marked pathological changes in the brain. 
Liver failure and portosystemic shunting of blood are two main factors underlying HE 
and the relative contribution of each varies from patient to patient [3].  We still do not 
know the exact nature of the biochemical “neurotoxins” that cause HE, but they are 
thought to be nitrogenous substances produced in the gut, possibly by bacterial action. 
These nitrogenous substances are normally metabolised by the healthy liver so that 
they do not enter the systemic circulation.   
Historically, ammonia was considered to be a key factor in the genesis of HE. 
Ammonia concentrations are raised in the systemic circulation and in the cerebral 
spinal fluid (CSF).  Previous studies have reported that in patients with advanced 
stages of HE, ammonia levels in the brain may increase more than twenty times 
normal levels [21]. Ammonia is known to inhibit cellular chloride channels, which 
contribute to depression of the central nervous system.  Ammonia also facilitates the 
uptake of tryptophan into the brain, which is a substrate for many metabolites, 
including serotonin.  Ammonia also decreases glutamatergic neurotransmission, 
causing neurodepression [3]. Evidence supporting the role of ammonia in the 
pathogenesis of HE is provided from observations that a syndrome resembling HE is 
produced by hyperammonoemia in the absence of cirrhosis or portosystemic shunting. 
In addition, a reduction of circulating ammonia concentrations by treatment with 
lactulose and antibiotics improves HE, and encephalopathy has been precipitated in 
patients with cirrhosis by administration of ammoniagenic substances [3].  However, 
ammonia cannot be the sole factor in HE as; (a) there is often a poor correlation 
between serum and CFS ammonia levels and the degree of HE, and (b) 
encephalopathy is sometimes observed in patients who have normal ammonia levels.  
Other possible explanations for HE include “false neurotransmitters” such as 
octopamine, amino acids, mercaptans, fatty acids  and endogenous benzodiazepines 
[22]. 
The role of endogenous benzodiazepines? 
Since 1989, a controversy has raged over the possible role that natural benzodiazepine 
(BZ) like substances may play in the pathogenesis of HE [22].  The natural or 
endogenous benzodiazepine hypothesis states that HE is the consequence of the 
accumulation of endogenous benzodiazepine-like substances  (“endozepines”)  in the 
brain.  It is proposed that these are either derived from the diet, or are produced in the 
gut by bacteria or fungi.  In people with significant cirrhosis, these endozepines are 
not removed by the liver, and accumulate in the systemic circulation.   The 
endozepines are thought to play a role in the development of HE by simulating the 
effects of exogenous benzodiazepines (e.g. diazepam) on brain function.   
Elevated levels of BZs have been found in rats and rabbits in fulminant hepatic failure 
[23, 24].    In an early human study, Mullen et al. reported greater binding of ligands 
to BZ receptors in CSF taken from patients with severe HE, and plasma BZ activity 
was also significantly higher, and correlated with HE severity [25]. This finding was 
also reported by Basile [26].   Olasma et al.  also reported markedly elevated levels of 
a diazepam like substance in the frontal cortex of patients who had died from 
fuliminant hepatic failure, and the levels were up to 10 times that found in the CSF of 
non-encephalopathic patients with liver disease [27].   Several studies since then have 
reported elevations in BZs in patients with HE, however, the overlap between 
comparison groups is often significant.  For example, Hernandez-Avila et al., [28] 
while finding elevated BZ levels in a group of HE patients, also reported that 20% of 
cirrhotic patients without HE had elevated BZ levels, and that a third of patients with 
HE had undetectable BZ levels.  They concluded “HE cannot be explained by the 
presence of these compounds alone” p.221 [28].  An important study was reported by 
Avallone et al. who compared a large group of patients with cirrhosis with healthy 
participants, but they also included a group of BZ consumers (regular users of 
diazepam or lorezapam as sedatives) [29]. When detectable, endogenous BZ levels in 
the cirrhotic group were comparable with those of the BZ consumers, but the levels 
correlated with the degree of liver dysfunction, not the stage of encephalopathy.  This 
led the authors to conclude that endogenous BZs appear to accumulate in some 
patients with cirrhosis during the course of their disease, but that this is not clearly 
related to the presence or stage of HE [29]. 
 
Reversing HE via BZ receptor antagonism 
The inhibitory tone of the BZ-GABA-ergic neurotransmitter system appears to be 
increased in HE [22], therefore it was logical to study the effects of drugs interacting 
with this system in the treatment of HE.  Flumazenil is a competitive BZ receptor 
antagonist, and has a high affinity for BZ receptors, rapidly reversing the hypnotic 
and sedative effects of BZs following intravenous administration.  Early uncontrolled 
clinical case-studies. reported  encephalopathic patients with cirrhosis waking from 
HE coma following flumazenil infusion e.g. [30].  Further uncontrolled group studies 
reported significant improvements in 60-70% of patients with HE following 
flumazenil infusion [31, 32].  The first randomised controlled-trial of HE using 
flumazenil versus placebo randomly allocated 11 patients to flumazenil and 10 to 
placebo infusion.  Six patients treated with flumazenil showed improved neurological 
symptoms whereas no participants in the control group showed improvement [33].  It 
is important to make two points about this much-cited study;  (a) 56 patients were 
excluded from the study because of potential confounders such as multi-organ failure 
or prior use of BZs, and (b) blood levels of BZ receptor ligands did not correlate with 
response to flumazenil.  In a subsequent randomised-controlled trial, Gyr et al 
reported a clinically significant immediate response to infusion in 7/28 flumazenil 
treated patients versus 0/21 in the placebo group, and concluded that a subgroup of 
patients with HE may benefit from flumazenil administration [34].  Most of the 
flumazenil studies have tested its efficacy in reversing severe HE, e.g. coma.  As 
stated above, however, mild HE is extremely common, and Gooday et al. [35] 
conducted a double-blind placebo-controlled cross-over study in patients with sub-
clinical HE using a low-dose (0.2mg/kg) flumazenil infusion versus saline, and found 
that reaction time (particularly cognitive, as opposed to motor speed) was 
significantly improved in patients and not healthy controls.  The authors concluded 
that endozepines may contribute to the psychomotor slowing that is commonly 
observed in HE, and they also raised the possibility that endozepines may be 
implicated in other psychopathalogical conditions where psychomotor retardation is 
prominent (e.g. major depression). 
A recent Cochrane review of BZ receptor antagonists for HE reviewed 13 randomised 
trials with a total of 805 patients.  All of the trials were double-blind and assessed 
flumazenil versus placebo.  Across studies, flumazenil was found to have a significant 
beneficial effect on improvement in HE at the end of treatment (risk difference 0.28; 
95% CI 0.20 to 0.37, 8 trials), but had no effect on recovery or mortality. Future 
research needs to determine if treatment with flumazenil leads to sustained 
improvement or increased recovery and survival.   Until this is demonstrated, 
flumazenil may be considered for patients with HE, but it cannot be recommended for 
routine clinical use [36]. 
The endogenous BZ explanation of HE has been a controversial hypothesis.  It has 
been suggested that it may not be the absolute level of BZ that is important, but rather 
changes in affinities or brain densities of BZ receptors [37]. 
Many have also argued that any effects attributed to endogenous benzodiazepines are, 
in fact, the result of (a) dietary origin, or (b) patients taking exogenous 
benzodiazepines surreptitiously.  It has also been suggested that any beneficial effects 
of flumazenil are likely to be attributable to its activity as an antidote to the BZ 
medications that are frequently prescribed to cirrhotic patients either as part of an 
endoscopic evaluation, or as a sedative.  It may be that flumazenil reverses the 
exogenous BZ effects in these patients, rather than treating HE itself [2]. In 
considering such claims, Desarathay & Mullen state: “Some may still consider 
exogenous ingestion of benzodiazepines to be the major cause of hepatic 
encephalopathy in cirrhotics and for finding benzodiazepines in their blood.  If that 
were true, then possibly the validity of the results of every study on the pathogenesis 
of hepatic encephalopathy since 1959, when benzodiazepines became available, 
would need to be questioned” p.765 [38]. 
HE is, in all probability, a multifactorial disorder, and while abnormalities of the 
GABA/BZ complex may play a role in some patients, it is extremely unlikely that 
endozepines account for all the neuropsychiatric manifestations of the syndrome [35]. 
 
Hepatic Encephalopathy – Cerebral localisation of dysfunction? 
The most common neuropsychological abnormalities in patients with varying degrees 
of HE is memory impairment and psychomotor slowing [39].  In an early study using 
cognitive assessment and single photon emission computerised tomography (SPECT), 
O’Carroll and colleagues compared a group of patients with cirrhosis who were 
considered by their physicians to be cognitively intact, and compared them with a 
group of age, gender and IQ matched healthy controls [12].  The cirrhotic group were 
significantly impaired on all cognitive tests relative to controls, with the exception of 
one, the Number Connection Test [10] – which just happens to be one of the tests that 
is the most widely used for the assessment of cognitive impairment in liver disease!  
The SPECT scans revealed bilateral hypermetabolism in the basal ganglia in patients 
with cirrhosis, and the degree of basal ganglia abnormality correlated with the degree 
of psychomotor slowing [12]. In the same year, Lockwood and colleagues conducted 
a similar study using positron emission tomography (PET) scans, and also reported 
increased regional cerebral blood flow in subcortical regions, particularly the 
thalamus and caudate [40].  Since then a number of structural brain scanning studies 
using magnetic resonance imaging (MRI) have confirmed abnormalities in sub-
cortical regions, e.g. the globus pallidus [41].   The degree of abnormality in these 
regions correlates with the degree of psychomotor impairment [42].  It appears that 
the abnormal MRI signal from the globus pallidus brain region in patients with 
cirrhosis may be caused by depositions of manganese.  Manganese is usually removed 
from the body by the hepatobiliary system, but when the liver is damaged the system 
does not function efficiently and the metal enters the brain and is deposited in the 
basal ganglia region [2].  Butterworth and colleagues reported manganese levels seven 
times higher than normal in the globus pallidus region of patients with cirrhosis [43].  
Taken together, this evidence suggests that manganese deposited in the basal ganglia 
may contribute to the psychomotor symptoms of HE. 
 
Using Neuropsychological Instruments to measure treatment response 
The development of neuropsychological measures over the past century has led to the 
accumulation of a vast number of cognitive tests which permit the valid and reliable 
quantification of various aspects of cognitive functioning.  This is particularly 
important when one is trying to determine subtle effects of interventions. As stated in 
the introduction, the traditional approach to measuring HE was by using the Parsons –
Smith criteria, which ranges from normal to coma in 5 stages – (not the most subtle of 
gradations!).  When clinical changes are not gross, they can be missed by bedside 
examination, and it has been proposed that the majority of patients with mild, but 
significant HE, are not detected routinely.  A major problem in cirrhosis is that the 
scarring leads to difficulty in the blood passing through the liver, and portal 
hypertension results.   This pressure can lead to the development of oesophageal 
varices (large swollen veins around the oesophagus).  Under consistent portal 
hypertension, these varices can rupture and bleed, and severe variceal bleeding is 
often fatal.  Portosystemic shunt surgery used to be the treatment of choice, where a 
shunt was inserted that effectively enabled blood to bypass the liver, thus rapidly 
reducing portal hypertension.  However, as the liver was effectively taken out of the 
circulatory loop, toxins continued to accumulate in the systemic circulation and HE 
often developed. In addition, the mortality associated with the procedure was high 
[44].  A more conservative alternative procedure was developed – transjugular 
intrahepatic portoystemic stent shunting (TIPPS).  TIPPS involves a small stent being 
placed between the portal vein and the hepatic vein in the liver to provide a 
portosystemic shunt to reduce portal pressure.  Successful shunt placement thus 
reduces portal hypertension and prevents variceal bleeding.  When TIPPS was 
introduced, a significant concern was whether the shunt would also lead to the gradual 
development of HE in recipients.  Rather than wait to see if full-blown HE and coma 
developed, neuropsychological assessment (e.g. of psychomotor speed and memory) 
has been conducted pre and post TIPPS, to see if the development of encephalopathy 
could be detected at an early stage.  Jalan et al. compared 29 TIPSS patients with 
healthy participants, and also included a group of cirrhotic patients who were not 
TIPPS candidates.  All participants were serially assessed using matched parallel 
versions of the neuropsychological tests in order to counter the effects of 
learning/practice effects [45].  Only 1 of the TIPPS patients developed HE over the 9 
month study period.  The study demonstrated the potential usefulness of repeated 
neuropsychological assessment, using sensitive measures with parallel versions, when 
evaluating interventions in liver disease. 
 
Liver Transplantation 
Perhaps the most radical treatment for liver disease is liver transplantation [46].  
Traditionally this involves the harvesting of a liver from a cadaver and transplanting 
the organ into the recipient.  This is either an elective procedure e.g. following 
evaluation and a period on a waiting list for patients with chronic liver disease, or is 
an acute response to fulminant hepatic failure, e.g. following paracetamol overdose.  
Liver transplantation has become a very well established procedure, with 5 year 
survival rates of around 75% commonly reported [47].  It is clearly a life-saving 
intervention for patients in liver failure.  However, increasing attention is being paid 
to evaluating psychological and social outcome in recipients, e.g. quality of life and 
cognitive functioning as key outcomes [48-51].  
For a three-year period (1996-1999) all patients who were evaluated for possible liver 
transplantation in Scotland underwent detailed psychological assessment by a trained 
psychologist [52]. The assessment covered the domains of mood, fatigue, cognitive 
functioning and quality of life (QoL).  All liver transplant recipients were assessed 
pre, and serially post transplant, and their performance was compared with two 
comparison groups; (a) healthy participants (hospital staff) and (b) patients with 
chronic liver disease who were not transplant candidates.  Cognitive impairment in 
transplant candidates was common, e.g. of 164 candidates assessed, only 21% 
performed within the normal memory range on the Rivermead Behavioural Memory 
Test [53], thus approximately 80% of transplant candidates had varying degrees of 
memory impairment. Also 45-60% of candidates had evidence of significant 
psychomotor slowing. In this national sample of liver transplant candidates, memory 
impairment and psychomotor slowing were therefore the norm.  This raises two 
issues; (a) the impact of this degree of cognitive impairment on the ability to give 
informed consent for a potentially life threatening procedure, and (b) the potential 
reversibility of this cognitive impairment following liver transplant.  When tested one  
year later, transplanted patients showed significant improvement on most 
psychological domains relative to both healthy comparison participants and patients 
with chronic liver disease who were not transplant candidates.  However, it is 
important to note that while the liver transplant recipients showed highly significant 
improvements in memory and psychomotor speed at 1 year post-transplant, their 
performance did not improve to the level of healthy participants. The liver transplant 
recipients’ mean scores for memory, simple and choice reaction time fell at a level 
similar to the control participants who had chronic liver disease, but were not 
transplant candidates – (see Figures 1& 2 for reaction time data).  These results 
suggest that while marked neuropsychological recovery is observed at 1 year post-
transplant, this recovery is incomplete, i.e. liver transplantation does not fully 
“normalise” cognitive performance, and that some residual degree of cognitive 
impairment remains [52].  It is often assumed that any cognitive impairment that is 
observed in liver disease is attributable to the neurotoxic effects of alcohol, however, 
the majority of participants in this study had a non-alcoholic aetiology (the most 
common diagnosis was primary biliary cirrhosis).  Furthermore, most studies do not 
report a differential outcome when comparing liver transplant for patients with 
alcohol versus a non-alcohol related aetiology. We do not know how, or if, the 
residual cognitive impairment we observed impacts upon day-to-day functioning, e.g. 
driving ability.  Further work is also required in order to test whether continuing 
recovery accrues over time.  This type of work highlights the importance of the 
sensitive and reliable assessment of neuropsychological status in determining the full 
impact of surgical and medical interventions in liver disease. 
 
Living Donor Liver Transplantation 
The above section described liver transplantation with organs retrieved from 
individuals who had died.  However, as a result of low donation rates, patients can 
often face a long wait for a new liver. Many patients consequently become too ill to 
go through with the transplant operation, or die before a suitable organ is found. The 
lack of organs from cadaveric donors is a problem found in every transplant unit 
throughout the UK and beyond.  Three out of four GPs believe that the UK should 
introduce an “opt-out” organ donor scheme. Within this scheme, organs from those 
who have died may automatically be removed and used to save the lives of those in 
need of transplants. This would happen unless the donor or their family specifies that 
organs may not be used in this way. The move, if adopted in the UK as it is in some 
other countries, could dramatically reduce the death rate among those currently 
awaiting transplantation. However, proposals for an “opt-out” scheme have repeatedly 
been rejected in the UK, and many patients continue to die while awaiting an organ 
transplant. Currently in Scotland, approximately one patient on the elective liver 
transplantation waiting list dies every month.  In an attempt to improve the situation, a 
radical alternative to donation from cadaveric donors has been developed.  This is 
known as Living Donor Liver Transplantation (LDLT), a groundbreaking treatment 
for serious liver disease.  LDLT enables a healthy family member to donate the right 
lobe of their liver (approximately 60 per cent of the liver mass) to a sick relative.  
LDLT has been described as “one of the most invasive procedures that could be 
contemplated for healthy individuals” p.24 [54].  Transplantation from a living donor 
is made possible through the liver’s unique ability to regenerate once it has been split. 
This is the case for both the part of the liver transplanted into the recipient and the 
part that remains in the donor.  
LDLT was first developed in Japan where organs from individuals who have died are 
not used for cultural reasons. Over the past 10 years, other countries such as North 
America, Asia, France and Germany have started to offer LDLT as an alternative to 
transplantation from non-heart beating donors.  In 2003, LDLT accounted for 5% of 
all liver transplants performed in the USA.   Although LDLT may seem like an ideal 
solution to the waiting list problem this “lifeline” comes at a cost. The healthy donor 
has to go through a major operation with no physical benefit to him or herself. The 
risk of death for the donor is considerable (originally estimated to be between 0.5 and 
1 per cent [55] and is far higher than the risk of death found when a person decides to 
donate one of their kidneys to a relative (0.03 per cent).  In addition, the risk of 
medical complications arising from the operation has been estimated at around 50 per 
cent [55]. However, as each centre that has developed an LDLT programme has had 
their own individual reporting methods, it is difficult to establish exact morbidity 
figures, e.g. a complication in one centre may not have been noted as such in another.  
The few quality of life studies that have been conducted following LDLT generally 
report positive outcomes (e.g. [56]).   However, approximately one third of donors felt 
that recovery took longer than expected, and a third to one half reported the pain as 
worse than expected.  In addition, 30-40% of donors reported that the surgical scar 
was worse than expected [54].  Complaints of throbbing, itching and numbness 
around the wound are relatively common [57].  In one study, “easily felt distress and 
anger” was reported by over 50% of donors following the LDLT procedure [57].  
A systematic review of LDLT outcomes has recently been published where 214 
studies which provided information on donor outcomes were analysed [54].  In this 
review, it is estimated that approximately 6,000 LDLT procedures have been 
performed worldwide, with 12 -13 donor deaths.  The calculated mortality for right 
lobe donors to adult recipients was 0.23 to 0.5%, with a median morbidity rate of 
16%.  The most commonly reported morbidities were biliary complications and 
infections [54].   
The authors of the recent systematic review state: “Although patient numbers are too 
small to determine clear patterns of causes of death after donation there is some 
indication that right lobe donors may not be left with sufficient liver reserve” [54] 
p.28.   An adult recipient needs the large right lobe of the donor’s liver to be 
transplanted into them, leaving the donor with the smaller left lobe of their liver. The 
liver starts to re-grow immediately after the transplant operation and regenerates to 
about double the size of the remnant liver within several months, reaching a median 
89% of the original liver size [54, 58]. It has still to be determined how this period of 
reduced liver mass (and potential hepatic insufficiency) in the months following 
LDLT impacts upon the cognitive status and functional capacity of the recovering 
donor.  For example, is 40% of the liver sufficient to remove toxins from the blood 
adequately, or is it possible that in the months following the operation, toxins 
accumulate in the systemic circulation, and a mild hepatic encephalopathic state 
develops, which gradually resolves over time as the liver regenerates in the donor?  
There is a paucity of evidence regarding such psychological outcomes following 
LDLT, as Caplan states “the pursuit of living donors as a source of lobes of liver for 
transplant has proceeded in something of a data vacuum” p.494 [59].   Further 
longitudinal research, using appropriately sensitive neuropsychological measures is 
urgently required in order to address this important issue [60]. 
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Figure 1
Changes in Simple Reaction Time by Group
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Figure 2
Changes in Choice Reaction Time by Group
Pre                        1 year later
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